Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJingrui SuiZPZhao PeiqiJXJunqing Xu

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds high efficacy of pola-R-CHP in CD5-positive DLBCL, suggesting early treatment optimization may be necessary.

Key Points

  • Rapid responses observed with an overall response rate of 92.6% after treatment.
  • The study involved 32 treatment-naïve patients, assessing treatments over 17.9 months.
  • Treatment with pola-R-CHP combined rituximab and doxorubicin, demonstrating effectiveness.
  • Highlights the importance of early therapeutic modifications in cases of incomplete remission.

Cite This Study

Sui et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d63chttps://doi.org/10.1182/blood-2025-1916
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study2026
  2. 2A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China2025
  3. 3Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China2025
  4. 4Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability2025
  5. 5Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China2025